Objectives: To evaluate and compare the efficacy and safety of Intranasal (IN) Dexmedetomidine, Midazolam and Ketamine in producing moderate sedation among uncooperative pediatric dental patients. Study Design: This randomized triple blind comparative study comprises of eighty four ASA grade I children of both sexes aged 4-14 years, who were uncooperative and could not be managed by conventional behavior management techniques. All the children were randomized to receive one of the four drug groups Dexmedetomidine 1?g/ kg (D1), 1.5μg/kg (D2), Midazolam 0.2mg/kg (M1) and Ketamine 5mg/kg (K1) through IN route. These drug groups were assessed for efficacy and safety by gauging overall success rate and by monitoring vital signs, respectively. Results: The onset of sedation was significantly rapid with M1 and K1 as compared to D1 and D2 (p=Ã0.001). The overall success rate was highest in D2 (85.7%) followed by D1 (81%), K1 (66.7%) and M1 (61.9%), however, the difference among them was not statistically significant (p=ã0.05). Even though all the vital signs were within physiological limits, there was significant reduction in pulse rate (PR) (p=Ã0.001) and systolic blood pressure (SBP) (p=Ã0.05) among D1 and D2 as compared to M1 and K1. D1, D2 and K1 produced greater intra- and post-operative analgesia as compared to M1. There were no significant adverse effects with any group. Conclusion: Dexmedetomidine, Midazolam and Ketamine, all the three drugs evaluated in the present study can be used safely and effectively through IN route in uncooperative pediatric dental patients for producing moderate sedation.

This content is only available as a PDF.
You do not currently have access to this content.